01/26
Headlines

ADHD

Mix Sector Stocks News: Alcobra Ltd. (NASDAQ:ADHD), United States Steel (NYSE:X), Buckeye Partners, L.P. (NYSE:BPL), Nautilus (NYSE:NLS), The Babcock & Wilcox (NYSE:BWC)

Ryan Holtz03 mins

Alcobra Ltd. (NASDAQ:ADHD) announced the pricing of its previously announced underwritten public offering of 6,500,000 ordinary shares at an offering price of $4 per share. Gross proceeds from the sale of the shares by Alcobra before underwriting discounts and commissions and other offering expenses are expected to be approximately $26 million. The offering is expected…

Read More

Watch 5 Stocks: Alcobra Ltd. (NASDAQ:ADHD), Ericsson (NASDAQ:ERIC), Gannett Co., Inc. (NYSE:GCI), Greatbatch, Inc. (NYSE:GB), Petrobras Argentina SA (NYSE:PZE)

Kristen Barton02 mins

Alcobra Ltd. (NASDAQ:ADHD) announced the pricing of its previously announced underwritten public offering of 6,500,000 ordinary shares at an offering price of $4 per share. Gross proceeds from the sale of the shares by Alcobra before underwriting discounts and commissions and other offering expenses are expected to be approximately $26 million. Alcobra Ltd. (NASDAQ:ADHD) belongs…

Read More

Gainers at Biotech: Alcobra (NASDAQ:ADHD), Aratana Therapeutics (NASDAQ:PETX), Northwest Biotherapeutics (NASDAQ:NWBO), Agenus Inc (NASDAQ:AGEN), AEterna Zentaris (NASDAQ:AEZS)

Jayne Crisman03 mins

Research analysts at WBB Securities initiated coverage on shares of Alcobra Ltd (NASDAQ:ADHD) in a report released on Thursday, 26 June 2014. The firm set a “hold” rating and a $18.00 price target on the stock. WBB Securities’ target price points to a potential upside of 5.76% from the company’s current price. Alcobra Ltd (NASDAQ:ADHD)…

Read More

Biotech Unusual Volume: Aldeyra Therapeutics (NASDAQ:ALDX), Alcobra (NASDAQ:ADHD), Receptos (NASDAQ:RCPT), Celsus Therapeutics (NASDAQ:CLTX)

John Meady02 mins

Aldeyra Therapeutics Inc (NASDAQ:ALDX) rallied to a new all-time high Thursday after Aegis Capital began coverage of the biotech company working to develop treatments for rare skin and eye diseases with a Buy rating. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was 12.26% in last session and finished the day at $7.51. Traded volume was 134,905.00million…

Read More